91 related articles for article (PubMed ID: 28864728)
1. mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter.
Roldan-Romero JM; Rodríguez-Moreno JF; García-Donás J; Rodríguez-Antona C
Clin Cancer Res; 2017 Sep; 23(17):5320. PubMed ID: 28864728
[No Abstract] [Full Text] [Related]
2. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
3. Genetics of renal cancer: focus on MTOR.
Ghosh AP; Sudarshan S
Aging (Albany NY); 2016 Mar; 8(3):421-2. PubMed ID: 27017990
[No Abstract] [Full Text] [Related]
4. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
[TBL] [Abstract][Full Text] [Related]
5. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
Tjota MY; Segal J; Stadler WM; Antic T
Pathology; 2021 Oct; 53(6):790-793. PubMed ID: 33509639
[No Abstract] [Full Text] [Related]
7. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.
Nogueira I; Dias F; Teixeira AL; Medeiros R
Pharmacogenomics; 2018 Feb; 19(3):249-261. PubMed ID: 29334302
[TBL] [Abstract][Full Text] [Related]
8. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
9. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR.
Xiang C; Cui SP; Ke Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):186-192. PubMed ID: 27072960
[TBL] [Abstract][Full Text] [Related]
10. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
12. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Nassar AH; Hamieh L; Gray KP; Thorner AR; Fay AP; Lasseter KD; Abou Alaiwi S; Nuzzo PV; Flippot R; Krajewski KM; Signoretti S; Choueiri TK; Kwiatkowski DJ
Mol Cancer Ther; 2020 Feb; 19(2):690-696. PubMed ID: 31653662
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.
Yang Z; Xie H; He D; Li L
Oncotarget; 2016 Jul; 7(28):44478-44491. PubMed ID: 27283897
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
Rua Fernández OR; Escala Cornejo R; Navarro Martín M; García Muñoz M; Antunez Plaza P; García Dominguez AR; Cruz Hernández JJ
Urology; 2018 Jul; 117():41-43. PubMed ID: 29702156
[TBL] [Abstract][Full Text] [Related]
16. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
[TBL] [Abstract][Full Text] [Related]
17. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
Malakar S; Chatterjee S; Das M; Pal DK
Urologia; 2024 May; 91(2):270-275. PubMed ID: 38205940
[TBL] [Abstract][Full Text] [Related]
19. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
20. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
